Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) is expected to post its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect Neumora Therapeutics to post earnings of ($0.46) per share for the quarter. Individual that wish to register for the company's earnings conference call can do so using this link.
Neumora Therapeutics Stock Performance
Shares of Neumora Therapeutics stock traded up $0.01 during trading hours on Friday, reaching $1.56. The company's stock had a trading volume of 1,956,909 shares, compared to its average volume of 4,424,587. The company has a market capitalization of $252.04 million, a P/E ratio of -0.83 and a beta of 2.50. The stock's fifty day simple moving average is $3.39 and its two-hundred day simple moving average is $8.97. Neumora Therapeutics has a one year low of $1.51 and a one year high of $21.00.
Analysts Set New Price Targets
NMRA has been the topic of several analyst reports. HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of Neumora Therapeutics in a report on Friday, February 14th. JPMorgan Chase & Co. downgraded Neumora Therapeutics from an "overweight" rating to a "neutral" rating and cut their target price for the stock from $18.00 to $15.00 in a research note on Tuesday, November 5th. Bank of America decreased their price target on Neumora Therapeutics from $22.00 to $7.00 and set a "buy" rating for the company in a research report on Monday, January 6th. Needham & Company LLC reissued a "buy" rating and issued a $23.00 price objective on shares of Neumora Therapeutics in a research report on Thursday, January 2nd. Finally, William Blair restated an "outperform" rating on shares of Neumora Therapeutics in a research note on Wednesday, January 15th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $16.50.
View Our Latest Stock Analysis on NMRA
About Neumora Therapeutics
(
Get Free Report)
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Read More
Before you consider Neumora Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neumora Therapeutics wasn't on the list.
While Neumora Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
